Bladder Cancer | Tumor

CURE’s bladder cancer page is a go-to resource for oncology news and updates in the world of bladder cancer. Here, readers will find cancer articles, videos, podcasts, and more with expert insight into the latest treatments and research in bladder cancer.

Cabometyx Failed to Improve Survival in Advanced Bladder Cancer

June 4th 2022

While Cabometyx had a favorable side effect profile, it did not lead to a significant survival advantage over placebo in a clinical trial.

Cancer Trial Hopes to Find New Patient Populations That Will Respond to Already-Approved Drugs

May 19th 2022

The Strata PATH trial will use a novel testing strategy to determine if certain patients with solid tumors can benefit from already-approved therapies.

First-in-Human Trial Assessing Novel Drug in Patients With Solid Tumors Launches

May 12th 2022

The primary objective of the early-stage trial is to determine the maximum tolerated dose of the novel drug in a group of patients with recurrent and/or refractory solid tumors.

Drug Commonly Used to Treat Rare Lung Condition May Improve Survival in Patients With Bladder Cancer

April 25th 2022

Treatment with a combination of Ofev and chemotherapy was shown to have a survival benefit in a group of patients with bladder cancer.

First Patient Treated in Study to Determine Tolerability, Dosing of Investigational Drug in Certain Solid Tumors

April 22nd 2022

Once a recommended dose of the drug is determined, the study investigators will review the efficacy and safety associated with this treatment across a variety of patients with bladder and liver cancer, as well other solid tumors.

Clinical Trials Come to a ‘Disappointing’ End When Drug Combo Fails to Improve Outcomes in Kidney and Bladder Cancer

April 19th 2022

The clinical development of BEMPEG plus Opdivo will end after clinical trials showed that the drug combination did not lead to significant improvements in outcomes in patients with kidney or bladder cancer.

Clinical Trial Assessing Keytruda-Investigational Drug Combo in Head and Neck, Bladder and Lung Cancer Doses First Patient

April 13th 2022

Investigators plan to enroll approximately 90 patients with squamous cell carcinoma of the head and neck, as well as metastatic bladder and non-small cell lung cancer.

Novel Treatment Given to First Patient in Trial Assessing the Drug’s Safety and Efficacy in Solid Tumors With Certain Genetic Alterations

April 6th 2022

Researchers have treated the first patient in the PRECISION 1 trial with Fyarro to assess the drug’s efficacy across several endpoints including survival among more than 100 patients with solid tumors that exhibit certain genetic alterations.

First Patient Receives Novel Antibody in Early-Phase Trial Assessing Safety, Efficacy of the Drug in Several Solid Tumor Types

April 4th 2022

A patient with an advanced solid tumor was given their first dose of a novel antibody, kicking off a phase 1/1b study comparing this drug with or without Keytruda in patients with several types of solid tumors.

First Patient Enrolled Onto Study Evaluating Zepzelca Monotherapy for Treatment of Certain Solid Tumors

March 29th 2022

Approximately 60 patients with metastatic/unresectable solid tumors, including bladder cancer, are expected to be enrolled onto a clinical trial assessing the safety and efficacy of Zepzelca.

First Patient Dosed in Early-Phase Trial Investigating a New Drug for Bladder Cancer

March 25th 2022

The trial will be testing TARA-002 in patients with non-muscle invasive bladder cancer with high-grade carcinoma in situ and high-grade papillary tumors.

‘Today Show’ Anchor Hoda Kotb Discusses Fertility Issues Following Cancer Diagnosis, Pfizer Pulls Blood Pressure Drugs Due to Cancer Concerns and More

March 25th 2022

From Pfizer issuing a voluntary recall of three blood pressure drugs due to a high level of a cancer-causing chemical to “Today Show” co-ancho Hoda Kotb discussing her struggles with fertility after receiving a diagnosis of breast cancer, here’s what’s happening in the cancer space this week.

Male Cancer Caregivers Navigate A Gauntlet of Challenges, Often Under The Cover of Darkness

March 15th 2022

Regardless of a man’s age, providing care to a partner or family member with cancer has been shown to take a drastic toll on their health. To make matters worse, research shows many men struggle in silence.

Immunotherapy Use Increased in Patients Ineligible for Cancer Trials, Highlighting the Need for More Research in Vulnerable Populations

December 28th 2021

The use of immunotherapy in patients with advanced cancers and decreased fitness levels or organ function increased from 2014 to 2019, although trials for this treatment typically exclude this population.

5 Cancer Clinical Trials You May Have Missed

December 18th 2021

There are many cancer clinical trials that patients can enroll in across the United States. Here is a snapshot of some of the more recent ones.

First Patient Receives Novel Immunotherapy in Bladder Cancer Sub-Study

November 13th 2021

The first patient with bladder cancer was dosed in a phase 1/2 trial examining responses to an investigational immunotherapy.

Side Effects From Immune Checkpoint Inhibitors May Increase Hospitalizations, Cost for Patients With Bladder, Liver, Lung or Skin Cancer

November 4th 2021

Patients who experience side effects due to immune checkpoint inhibitors are 80% more likely to go to the emergency room and have 30% higher monthly medical costs, compared to patients who did not have side effects.

New Trial Initiated for Fosciclopirox in Patients With Bladder Cancer

October 26th 2021

A phase 1b trial started to study the effects of fosciclopirox in patients with newly diagnosed and recurrent bladder cancer.

Trial Initiated to Assess Efficacy of Cosela in Bladder Cancer

October 14th 2021

The PRESERVE 3 trial began this summer to determine efficacy of using Cosela with platinum-based chemotherapy in patients with metastatic bladder cancer.

Here’s How Men With Bladder, Colorectal and Prostate Cancer Can Treat Sexual Dysfunction

October 5th 2021

Treatments for bladder, colorectal and prostate cancer may cause sexual dysfunction in men. Here, an expert provides insight into how patients and survivors may improve their sexual health.

Cancer and Ostomies: A World Ostomy Day Perspective

October 2nd 2021

A bladder cancer survivor discusses the importance of World Ostomy Day and shares her own ostomy story.

Here's Why Collaboration Is Important for Progress in Genitourinary Cancers

September 26th 2021

It is important that the whole community understand that basic research and clinical trials can continue to improve outcomes for patients with genitourinary cancer.

Inside the Shifting Treatment Landscape for Advanced Genitourinary Cancers

September 25th 2021

In this special issue of CURE®, we spoke with patients and health care providers about fertility issues, treatment advancements and other topics related to kidney, prostate, testicular and bladder cancers.

New Agent Can Improve BCG Response, Quality of Life in Bladder Cancer

September 18th 2021

The novel drug N-803 boosted response to Bacille Calmette-Guérin therapy in patients with non-muscle invasive bladder cancer, a study showed.

Lack of Smoking Data in Bladder, Kidney and Prostate Cancer Clinical Trials May Affect Patient Outcomes

September 17th 2021

Clinical trials that are designed to ask patients with bladder, kidney and prostate cancer about their smoking status may help patients better understand what to expect from their treatment based on their smoking habits.

Phase 2 BCG-Unresponsive Bladder Cancer Study Gets the OK to Start Enrollment

September 1st 2021

Patients with Bacillus Calmette Guérin-unresponsive carcinoma in-situ will be treated at the University of Chicago in a Theralase study.

FDA Expands Indication of Keytruda for Bladder Cancer Subtype

August 31st 2021

Keytruda is now indicated for the treatment of locally advanced or metastatic urothelial carcinoma, a type of bladder cancer, although an unmet need remains in the treatment of these patients.

FDA’s Recent Approval of Trodelvy Delivers Promising Treatment Option for Metastatic Bladder Cancer

August 23rd 2021

A recently approved antibody-drug conjugate provides another much-needed treatment choice for patients with locally advanced and metastatic urothelial cancer.

Patient Recruitment Has Begun for Trial Assessing Cosela in Metastatic Bladder Cancer

August 20th 2021

Preliminary results of the phase 2 trial assessing the safety and efficacy of Cosela with gemcitabine/platinum-based chemotherapy and Bavencio maintenance therapy for metastatic bladder cancer are expected to be released in the second half of 2022.

FDA Approves Opdivo for Adjuvant Treatment in Bladder Cancer

August 20th 2021

The FDA granted approval to Opdivo as an adjuvant treatment in patients with high-risk urothelial carcinoma.

NEXT PAGE
PREVIOUS PAGE